Literature DB >> 12673163

A comparative study of 11C-choline PET and [18F]fluorodeoxyglucose PET in the evaluation of lung cancer.

N Khan1, N Oriuchi, H Zhang, T Higuchi, M Tian, T Inoue, N Sato, K Endo.   

Abstract

The purpose of this study was to compare the diagnostic value of 11C-choline positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) PET imaging in the detection of primary lung cancer and mediastinal lymph node metastases. Seventeen patients with histologically proven primary lung cancer were examined with both 11C-choline and FDG PET within a week of each study. Lung cancers were analysed visually and semiquantitatively using the ratio of tumour-to-normal radioactivity (T/N ratio) and standardized uptake value (SUV). Mediastinal lymph node metastases were analysed visually. Although both techniques delineated focal lesions with an increase in tracer accumulation in 13 patients, FDG PET identified three additional patients in whom 11C-choline PET did not visualize any lesion. In the detection of lung cancer <2 cm in size, FDG PET provided higher sensitivity (six of seven, 85.7%) than 11C-choline PET (four of seven, 57.1%). The T/N ratio and SUV were significantly higher with FDG PET (T/N ratio, 7.43+/-6.22; SUV, 4.05+/-3.05) than these were with 11C-choline PET (T/N ratio, 2.93+/-1.19; SUV, 2.93+/-0.79) (P<0.001). There was a significant positive correlation between the T/N ratios and SUVs of FDG and 11C-choline. In the assessment of mediastinal lymph node involvement, FDG PET detected lymph node metastases in two patients who were negative on 11C-choline PET, whereas both techniques could not detect tumour involvement in one patient. Both techniques have clinical value for the non-invasive detection of primary lung cancer that is 2 cm or greater in size. However, FDG PET is superior to 11C-choline PET in the detection of lung cancer that is less than 2 cm in diameter and in mediastinal lymph node metastases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673163     DOI: 10.1097/00006231-200304000-00004

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Could choline PET play a role in malignancies other than prostate cancer?

Authors:  Cristina Nanni; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-26       Impact factor: 9.236

Review 2.  PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature.

Authors:  Koen Mertens; Dominique Slaets; Bieke Lambert; Marjan Acou; Filip De Vos; Ingeborg Goethals
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-11       Impact factor: 9.236

Review 3.  Imaging for Target Delineation and Treatment Planning in Radiation Oncology: Current and Emerging Techniques.

Authors:  Sonja Stieb; Brigid McDonald; Mary Gronberg; Grete May Engeseth; Renjie He; Clifton David Fuller
Journal:  Hematol Oncol Clin North Am       Date:  2019-09-17       Impact factor: 3.722

4.  Use of ¹¹C-Choline positron emission tomography/computed tomography to investigate the mechanism of choline metabolism in lung cancer.

Authors:  Zhaoqin Huang; Jun Rui; Xin Li; Xiangjiao Meng; Qingwei Liu
Journal:  Mol Med Rep       Date:  2015-01-14       Impact factor: 2.952

Review 5.  Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy.

Authors:  Valeria Panebianco; Flavio Barchetti; Daniela Musio; Francesca De Felice; Camilla Proietti; Elena Lucia Indino; Valentina Megna; Orazio Schillaci; Carlo Catalano; Vincenzo Tombolini
Journal:  Biomed Res Int       Date:  2014-03-13       Impact factor: 3.411

6.  Spatial heterogeneity of radiolabeled choline positron emission tomography in tumors of patients with non-small cell lung cancer: first-in-patient evaluation of [18F]fluoromethyl-(1,2-2H4)-choline.

Authors:  Suraiya Dubash; Marianna Inglese; Francesco Mauri; Kasia Kozlowski; Pritesh Trivedi; Mubarik Arshad; Amarnath Challapalli; Tara Barwick; Adil Al-Nahhas; Rex Stanbridge; Conrad Lewanski; Matthew Berry; Frances Bowen; Eric O Aboagye
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.